The service will provide compounding pharmacy services to healthcare providers.
Revelation Pharma is going national with its compounding network.
The network of 503A and 503B compounding pharmacies launched a national wholesale service for healthcare providers.1 Revelation Wholesale is designed to provide users with a streamlined ordering process when purchasing compounding solutions and unique medications.
In a press release, Revelation Pharma’s national director of wholesale Shelby Owens said, “The launch of Revelation Wholesale is monumental for us and has been a true labor of love. In my over 25 years of experience, I've had the opportunity to lead some incredibly fulfilling projects, and Revelation Wholesale is one that stands out."
In the same press release, Revelation Pharma CEO Shawn Hodges added, “At Revelation Pharma, we are not just suppliers, we are collaborators, and all our work is underscored by the desire to promote well-being through the advancement in healthcare excellence. The launch of Revelation Wholesale is just another indication of our commitment, and we look forward to seeing the value it brings to providers and patients."
Revelation Pharma has made several steps this year to increase its presence across the nation. In July, the company announced that it had acquired Taylors Pharmacy and Key Compounding to expand its access in Florida and Washington state.2
In a press release issued at the time, Hodges said, “At Revelation Pharma, we aim to touch as many lives as possible through our vast range of compounding services. With the addition of Taylors Pharmacy and Key Compounding Pharmacy to the Revelation Pharma compounding network, we will further enhance that goal. We look forward to supporting both pharmacies in their dedication to their patients."
Allen Deaver, founder of Taylors Pharmacy also said, “As a pharmacy of humble beginnings, expanding our services and reaching more patients has been so fulfilling for us every step of the way. Becoming a part of the Revelation Pharma network helps us continue down that path, and we're thrilled for the opportunity."
"To join the Revelation Pharma national network of compounding pharmacies is a big step for us, especially as we look to the future in how we support our patients who have come to rely on us over the years," added HeeJoo Park, owner of Key Compounding Pharmacy. "We're excited for what's to come by this addition to the Key Compounding Pharmacy story."
In May, Revelation Pharma launched Consult RX, a nationwide service for healthcare providers and patients alike.3
At the time, Revelation Pharma VP of clinical and marketing services Tara Thompson, PharmD, FAPC, said, “The development of ConsultRX was a natural, organic move as it aligns with our commitment to delivering best-of-the-best care, which benefits patients and healthcare providers alike. Our team's passion for solving various healthcare issues in a compounding setting is our foremost priority, and we're confident ConsultRX in its consulting capabilities, will further our ability to achieve that."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.